金币
UID384689
帖子
主题
积分541
注册时间2018-9-3
最后登录1970-1-1
听众
性别保密
|
楼主 |
发表于 2019-1-31 15:23:05
|
显示全部楼层
6.Risk Assessment 风险评估
6.1 Under ICH Q9, risk assessment is broken into three stages: risk identification, risk analysis, and risk evaluation.
基于ICH Q9,风险评估可分为三个阶段:风险识别,风险分析,风险评估
6.2 Risk can be defined as: risk = f (probability of occurrence of harm and the severity of that harm).
风险可以被定义为:风险=f(发生的可能性及损害的严重程度)
6.3 For the purposes of cleaning, risk can be further defined as a function of the severity of the hazards of process residues,likelihood and level of process residues, and detectability of process residues.
对于清洁来说,风险可以进一步定义为工艺残留危害的严重程度、工艺残留的可能性和级别以及工艺残留物的可检测性三者之间的函数。
6.4 For a reliable assessment of risk, scientific means (for example, risk management tools) should be used to identify the hazard presented by a process residue (for example, API, degradation products, intermediates, cleaning agent, bioburden/endotoxin, and so forth), the ability of a cleaning process to remove process residues to levels that are acceptable, and the ability to detect and quantify the presence of process residues after cleaning.
对于一个可靠的风险评估,科学手段(例如,风险管理工具)应当用于识别工艺残留风险(例如,API、产品分解物、中间体、清洁剂、生物负载/内毒素等等)、将过程残留物清除到可接受水平的能力、清洗后检测和量化工艺残留物的能力。
6.5 Risk Identification—Risk identification should encompass the identification of process residue hazards, equipment design hazards, and procedural hazards.
风险识别-风险识别应包含工艺残留风险、设备设计风险和程序风险的识别。
6.5.1 Process Residue Hazard Identification 工艺残留风险识别:
6.5.1.1 The hazard presented by a potential process residue may be determined from a toxicological review performed by a qualified toxicologist or qualified pharmacologist. 一个潜在的工艺残留物的危害可以由一个有资质的毒理学家或合格的药理学家进行毒理学检查来确定。For an API, this involves a thorough review of all relevant toxicologi- cal data available for the process residue under study (9). When preclinical and clinical data on APIs are available to review, an ADE can be determined and used as a measure of the severity of hazard presented by a compound. For further information,see the ISPE Risk-MaPP Guide (1) or the EMA Guideline on Setting Health Based Exposure Limits for Use in Risk Identi- fication in the Manufacture of Different Medicinal Products in Shared Facilities Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities.
对于原料药来说,这需要对研究中残留的所有相关毒理学数据进行彻底的审查(9)。当有关于原料药的临床前和临床数据可供审查时,就可以确定ADE,并将其作为衡量化合物危害程度的指标。有关更多信息,请参见ISPE Risk-MaPP指南(1)或EMA指南:在共用设施中生产不同药品的风险识别和设置基于健康的暴露限值。
6.5.1.2 When an ADE is not available, such as for intermediates, degradation products, or compounds in early development, alternative approaches such as the threshold of toxicological concern (TTC) may be justified (9, 10).Although compounds in early development may not have sufficient safety data to perform a complete analysis, useful information can be found in the chemical structure of a compound to help determine a provisional ADE for the compound. “In silico” (computer-assisted) toxicological assessment or a structure activity relationship can be used to determine provisional ADEs for a compound (11, 12).For example, a compound in the same structural series of a known API from a given therapeutic class can be treated in the same way as that API,for example, a compound with a propylamine structure would be expected to share properties of this class of antihistamines.Where data are available on comparative potency, these can be used to adjust the estimated ADE.
当ADE值无法获取,例如中间体、产品分解物、或处于早期开发研究阶段的化合物,可用替代方法,例如毒理学阈值(TTC)可能是可行的。虽然早期开发的化合物可能没有足够的数据来执行完整的分析,但在化合物的化学结构中可以找到有用的信息,以帮助确定化合物的假定ADE。“In silico”(计算机辅助)毒理学评估或结构活性关系可用于确定化合物的ADE(11,12)。例如,与特定治疗类的已知原料药具有相同结构序列的化合物可以采用与该原料药相同的方法进行治疗。例如,一种具有丙胺结构的化合物可能具有这类抗组胺药物的共同特性。如果有关于比较药效的数据,这些数据可用于调整估计的ADE。
6.5.1.3 The hazard of possible bioburden from a previous product and the possibility of microbial proliferation after a cleaning process and the hazards this presents,including the need for subsequent disinfection, should also be considered.For example, the hazard(s) presented by holding equipment either in a dirty state or in clean state should be considered or the possibility of endotoxin and the need for subsequent depyrogenation should be considered.
还应考虑前一生产产品中可能产生的生物污染的风险以及清洗过程后微生物增殖的可能性及其带来的风险,以及是否需要进行随后的消毒。例如,应考虑保持设备处于未清洁状态或清洁后状态所带来的风险,或者应该考虑内毒素的可能性以及随后脱硫的必要性。
6.5.2 Equipment Hazard Identification—The potential hazards presented by equipment design should also be considered,such as the possibility of product buildup. Equipment should be designed to facilitate cleaning, inspection, and monitoring.
设备风险识别—应考虑设备设计中可能出现的风险,比如产品残留的可能性。设备的设计应便于清洗、检查和监视。
6.5.3 Procedural Hazard Identification—Before use, cleaning procedures should be subjected to risk assessments,for example, cleaning FMEA or other risk management tools, to minimize risk of failure (for example, to ensure that product buildup is avoided),improve the cleaning procedures, and make the cleaning procedures more reliable and robust.
清洁方案风险评估—在使用前,清洁方案应进行风险评估,例如,清洁FMEA评估或其他风险管理工具,以减少失败的风险(例如,确保避免产品积聚),完善清洁方案,使清洁方案更加可靠、稳健。 |
|